Plozasiran (ARO-APOC3) Decreases APOC3 and Triglycerides (TG) in Patients With Mixed Hyperlipidemia: MUIR Final Results

Published: April 30, 2024, 4 a.m.

Host: Christie M. Ballantyne, MD, FACP, FACC
\n\n\n \n

This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.